Adelaide, Australia, April 25, 2018 -- OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the first set of HipAlign® cases successfully completed for direct anterior total hip arthroplasty (THA) in Australia. These cases were completed by Adelaide-based orthopaedic surgeon Dr. Andrew Comley and continue to reflect the rapid adoption of OrthAlign's handheld precision alignment and positioning technologies, by surgeons throughout the world.
OrthAlign provides highly accurate, computer-assisted, handheld technologies for surgeons to receive real-time, actionable data for precise alignment and positioning of components in total knee, unicondylar knee, and total hip (both posterior and anterior) arthroplasty surgeries. Over 15 peer-reviewed clinical studies have been published to date, validating OrthAlign's accuracy, simplicity of use, and benefits in recovery for the patient.
"The accuracy and simplicity of HipAlign was outstanding," said Dr. Comley, who operates out of Wakefield Hospital in Adelaide. "The technology is very easy to use with no interruption to my regular workflow and my post-ops showed that the cups were placed where I wanted them. I have increasingly been using the Direct Anterior approach for my THA patients and I have definitely seen the benefits for them... I will continue using the technology, as I believe it is the right thing for my patients, giving me more confidence and precision toward their results. Additionally, I teach and mentor younger surgeons who wish to master the Direct Anterior technique and I believe HipAlign can provide a valuable teaching tool and reassurance for those surgeons on the learning curve."
Direct Anterior HipAlign does not require any pre-operative imaging or intraoperative fluoroscopy, while providing more clinically relevant positioning for cup placement and leg length measurement. Early clinical data from the United States demonstrates that surgeons can expect to reduce fluoroscopy exposure time by about 45%. Early clinical data from Japan shows cup placement (for both inclination and anteversion) accuracy of ±10°, with at least 95.9% confidence.
“OrthAlign is delighted to have successfully completed its first HipAlign cases in Australia," said Andy Turner, OrthAlign’s Country Director for Australia/New Zealand. “The Australian market is thirsting for a cost-effective solution that helps surgeons achieve quicker, more precise results for their THA patients, without having to alter their existing surgical workflows. We are thrilled to be starting our launch of HipAlign for Direct Anterior THAs here in Australia and that it will not only help surgeons gain more confidence in their surgeries, but also lead to better outcomes for patients.”
About OrthAlign, Inc.
OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit www.orthalign.com.
James Young Kim OrthAlign, Inc. +1-949-525-9027 [email protected]


Meta, U.S. States Discuss Settlement in Teen Addiction Trial
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
OpenAI AI Agent Swarm Behind Hugging Face Hack
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7%
Tesla Raises Cybertruck Prices by $5,000 in US
Trump Buys SpaceX Shares After Record IPO
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 



